XJPX4889
Market cap21mUSD
Dec 26, Last price
271.00JPY
1D
-0.37%
1Q
-22.35%
IPO
-63.38%
Name
Renascience Inc
Chart & Performance
P/E
—
P/S
17.74
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
194m
+93.11%
Net income
-258m
L-23.07%
CFO
-231m
L-19.01%
Profile
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | |
| Income | |||||
Revenues | 194,165 93.11% | 100,545 -27.84% | 139,333 -33.59% | ||
Cost of revenue | 432,331 | 420,250 | 333,363 | ||
Unusual Expense (Income) | |||||
NOPBT | (238,166) | (319,705) | (194,030) | ||
NOPBT Margin | |||||
Operating Taxes | 1,957 | 1,958 | 1,204 | ||
Tax Rate | |||||
NOPAT | (240,123) | (321,663) | (195,234) | ||
Net income | (258,335) -23.07% | (335,797) 32.05% | (254,292) 154.15% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 1,868,083 | ||||
BB yield | -36.78% | ||||
| Debt | |||||
Debt current | |||||
Long-term debt | 356,100 | 309,600 | 199,228 | ||
Deferred revenue | |||||
Other long-term liabilities | 1,000 | 1,000 | |||
Net debt | (1,672,790) | (1,904,877) | (2,193,285) | ||
| Cash flow | |||||
Cash from operating activities | (230,519) | (284,641) | (230,492) | ||
CAPEX | (1,577) | (2,225) | (1,164) | ||
Cash from investing activities | (1,567) | 232 | (296) | ||
Cash from financing activities | 46,500 | 110,371 | 1,591,662 | ||
FCF | (235,822) | (322,334) | (195,283) | ||
| Balance | |||||
Cash | 2,026,890 | 2,212,477 | 2,386,513 | ||
Long term investments | 2,000 | 2,000 | 6,000 | ||
Excess cash | 2,019,182 | 2,209,450 | 2,385,546 | ||
Stockholders' equity | 88,329 | 347,664 | 682,462 | ||
Invested Capital | 1,874,496 | 1,818,335 | 1,703,009 | ||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 12,712 | 12,712 | 11,389 | ||
Price | 381.00 -14.96% | 448.00 0.45% | 446.00 | ||
Market cap | 4,843,158 -14.96% | 5,694,842 12.11% | 5,079,548 | ||
EV | 3,170,368 | 3,789,965 | 2,886,263 | ||
EBITDA | (236,220) | (318,327) | (190,956) | ||
EV/EBITDA | |||||
Interest | 5,366 | ||||
Interest/NOPBT | |||||